Aarhus University logo

    • About
      • About the Nordic EMBL Partnership
      • Mission statement
      • EMBL non-tenure model
      • Contact
    • News
    • Collaborations
      • NORPOD - Postdoctoral Researcher Programme
      • NordForsk: Nordic EMBL Partnership Hub
      • How the Nordic EMBL Partnership is helping to fight COVID-19
      • Tools of the Trade Data Science Webinar Series
      • Nordic EMBL Partnership Meetings
      • Nordic EMBL Partnership Science and Art
    • Research
    • Technologies
    • Training
    • Careers
    • Internal

    Read more

    Click here to read more

    DANDRITE

    The Danish Research Institute of Translational Neuroscience (DANDRITE) is the Danish node of the Nordic EMBL Partnership, and performs basic and translational research in brain and the nervous system.

    FIMM

    The Institute for Molecular Medicine Finland (FIMM) is the Finnish node of the Nordic EMBL Partnership. FIMM’s research interests are human genomics and personalized medicine, with a focus on translational research.

    MIMS

    The Laboratory for Molecular Infection Medicine Sweden (MIMS) is the Swedish node of the Nordic EMBL Partnership. MIMS aims to strengthen Swedish research and enhance the dynamics in the field of molecular medicine.

    NCMBM

    The Norwegian Centre for Molecular Biosciences and Medicine (NCMBM) is the Norwegian node of the Nordic EMBL Partnership. NCMBM conducts molecular medicine & biotech research and works to translate these findings into clinical practice. 

    News from the Partnership


    AU start-up receives support for the development of a new medical spin-out

    From the left: Claus Elsborg Olesen, Poul Henning Jensen, Lasse Reimer and William Dalby-Brown. Credit: BioInnovation Institute/Esben Zøllner Olesen
    03 March 2025 - Knowledge exchange

    DANDRITE researchers are among the 12 selected for a prestigious entrepreneurship program aimed at advancing their groundbreaking research on cellular…

    2024 MIMS Clinical Research Fellowships awarded

    31 January 2025 - Knowledge exchange

    The Laboratory for Molecular Infection Medicine Sweden (MIMS) has this week announced the winners of its national Clinical Research Fellowship (CRF)…

    The evolution of the immune system – love at first sight

    Ryo Morimoto collects snails from the aquarium. His passion lies in basic science, with a focus on unravelling the pathophysiology of various human diseases, which may also have implications for clinical medicine.  Image: Mattias Pettersson
    13 January 2025 - Knowledge exchange

    Ryo Morimoto unpacks many moving boxes from Germany and sets up snail aquariums while establishing his new laboratory at Umeå University.

    “I believe…

    Alumni Group Leader Mark Denham: “If you had asked me ten years ago if I’d be in this position after nine years, I would have said; ‘That would be amazing’.”

    Graphical illustration of Mark Denham's research in stem cells Artist: Mette Stentoft
    17 December 2024 - Knowledge exchange

    Mark Denham was the first researcher to work with stem cells at Aarhus University when he joined as a new Group Leader at DANDRITE in 2013. Today, his…

    Page 2 of 70.

    • Previous
    • 1
    • 2
    • 3
    • …
    • 70
    • Next

    Upcoming Partnership Events


    No events found.

    Follow us!

    Follow us for the latest updates and insights! Join our community and stay connected with us on the following platforms

    LinkedIn
    Bluesky
    X

     

    About 

    News 

    Collaborations

    Research

    Technologies

    Training

    Careers

     

     

     

    Follow us

    X: @NordicEMBL

    LinkedIn: linkedin.com/company/nordic-embl-partnership-for-molecular-medicine

     

    The Nordic EMBL Partnership for Molecular Medicine combines the complementary research expertise of the Nordic countries with a common aim to address some of the biggest challenges in biomedicine today.

     

    Revised 21.03.2025

    © — Cookies at au.dk
    Privacy Policy
    Accessibility Statement

    15450 / i43